NCT06079424 Risk Markers of Arterial Aging. The Paris Prospective Study III-2
| NCT ID | NCT06079424 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institut National de la Santé Et de la Recherche Médicale, France |
| Condition | Arterial Stiffness |
| Study Type | OBSERVATIONAL |
| Enrollment | 7,500 participants |
| Start Date | 2025-06-20 |
| Primary Completion | 2031-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 7,500 participants in total. It began in 2025-06-20 with a primary completion date of 2031-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The main objectives of PPS3-2 are (i) to describe the dynamics of vascular aging and baroreflex sensitivity 12 to 16 years a part, (ii) to identify their determinants, and (iii) to quantify the subsequent risk of cardiovascular diseases.
Eligibility Criteria
Inclusion Criteria: * Being enrolled in PPS3 and having signed an informed consent for PPS3-2 Exclusion Criteria: * Institutionalized participants * Participants under guardianship * Participants under judicial safeguard measure
Contact & Investigator
Jean-Philippe Empana, MD, PhD
PRINCIPAL INVESTIGATOR
Institut National de la Santé Et de la Recherche Médicale, France
Frequently Asked Questions
Who can join the NCT06079424 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, up to 95 Years, studying Arterial Stiffness. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06079424 currently recruiting?
Yes, NCT06079424 is actively recruiting participants. Contact the research team at jean-philippe.empana@inserm.fr for enrollment information.
Where is the NCT06079424 trial being conducted?
This trial is being conducted at Paris, France.
Who is sponsoring the NCT06079424 clinical trial?
NCT06079424 is sponsored by Institut National de la Santé Et de la Recherche Médicale, France. The principal investigator is Jean-Philippe Empana, MD, PhD at Institut National de la Santé Et de la Recherche Médicale, France. The trial plans to enroll 7,500 participants.